email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
1066 - 1080
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
LianBio Completes $325 Million US IPO to Support China In-Licensing Program
$5.00
Available
BeiGene Pays $45 Million Upfront for Global Rights to Shoreline Cell Therapies
$5.00
Available
HitGen Subsidiary Forms Partnership to Develop Novel Cancer Drug
$5.00
Available
Junshi and Coherus File for US Approval of Partnered PD-1
$5.00
Available
Shanghai Pharma Unit Acquires Microbiome Therapies in $110 Million Deal
$5.00
Available
Alphamab Starts China Phase II/III Trial of PD-L1/CTLA-4 Bispecific
$5.00
Available
Novadip's $22 Million B Round for Skeletal Tissue Therapies Includes HK Investor
$5.00
Available
Innovent and NeoCura to Test PD-1/mRNA Vaccine Combination for Cancer
$5.00
Available
Fosun Announces $628 Million Deal for Majority Stake in Chengdu Antejin
$5.00
Available
CANbridge Doses First Patient in Phase II GBM Trial
$5.00
Available
SciNeuro Partners with Mabylon to Discover Antibodies for Neurological Diseases
$5.00
Available
Angel to Start China Trial of ITK Inhibitor for Lymphoma
$5.00
Available
Silenseed Raises $7.8 Million for China RNAi Joint Venture
$5.00
Available
CANbridge to Acquire Gene Therapy for Rare Diseases from Scriptr
$5.00
Available
Kintor Approved to Start Phase I Trial of Dual-Targeting Antibody
$5.00
Available